{{Drugbox
| Verifiedfields = changed
| Watchedfields = changed
| verifiedrevid = 403346583
| IUPAC_name = (2''S'',5''R'',6''R'')-6-[(''E''/''Z'')-(azepan-1-ylmethylene)amino]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid
| image = Mecillinam2DCSD.svg
| image2 = Mecillinam-3D-balls.png
| drug_name = 
<!--Clinical data-->
| tradename = Coactin, Leo, Selexid, Selexidin
| Drugs.com = {{drugs.com|international|amdinocillin}}
| pregnancy_AU = <!-- A / B1 / B2 / B3 / C / D / X -->
| pregnancy_US = <!-- A / B / C / D / X -->
| pregnancy_category = Appears safe in pregnancy<ref name=Nicolle>{{cite journal | author = Nicolle LE | title = Pivmecillinam in the treatment of urinary tract infections | journal = J Antimicrob Chemother | volume = 46  | issue =Suppl A | pages = 35–39 |date=August 2000 | pmid = 10969050 | doi = 10.1093/jac/46.suppl_1.35 | url =http://jac.oxfordjournals.org/content/46/suppl_1/35.long}}</ref>
| legal_AU = S4
| legal_CA = <!--                             / Schedule I, II, III, IV, V, VI, VII, VIII -->
| legal_UK = POM
| legal_US = <!-- OTC                   / Rx-only  / Schedule I, II, III, IV, V -->
| legal_status = Rx-only
| routes_of_administration = [[Intravenous therapy|Intravenous]], [[intramuscular injection|intramuscular]]
<!--Pharmacokinetic data-->
| bioavailability = Negligible
| protein_bound = 5 to 10%
| metabolism = Some [[liver|hepatic]] metabolism
| elimination_half-life = 1 to 3 hours
| excretion = [[Kidney|Renal]] and biliary, mostly unchanged
<!--Identifiers-->
| CAS_number_Ref = {{cascite|correct|??}}
| CAS_number = 32887-01-7
| CAS_supplemental =  
| ATC_prefix = J01
| ATC_suffix = CA11
| ATC_supplemental =  
| PubChem = 36273
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
| DrugBank = DB01163
| ChemSpiderID_Ref = {{chemspidercite|changed|chemspider}}
| ChemSpiderID = 33357
| UNII_Ref = {{fdacite|changed|FDA}}
| UNII = V10579P3QZ
| KEGG_Ref = {{keggcite|changed|kegg}}
| KEGG = D02888
| ChEMBL_Ref = {{ebicite|correct|EBI}}
| ChEMBL = 530
<!--Chemical data-->
| C=15 | H=23 | N=3 | O=3 | S=1
| molecular_weight = 325.426 g/mol
| smiles = CC1([C@@H](N2[C@H](S1)[C@@H](C2=O)N=CN3CCCCCC3)C(=O)O)C
}}
'''Mecillinam''' ([[International Nonproprietary Name|INN]]) or '''amdinocillin''' ([[United States Adopted Name|USAN]]) is an extended-spectrum [[penicillin]] [[antibiotic]] that binds specifically to [[penicillin binding proteins|penicillin binding protein 2]] (PBP2),<ref name=Neu>{{cite journal |author=Neu HC |title=Amdinocillin: a novel penicillin. Antibacterial activity, pharmacology and clinical use |journal=Pharmacotherapy |volume=5 |issue=1 |pages=1–10 |year=1985 |pmid=3885172 |doi= 10.1002/j.1875-9114.1985.tb04448.x|url=}}</ref> and is only considered to be active against [[Gram-negative bacteria]]. It is used primarily in the treatment of [[urinary tract infection]]s, and has also been used to treat [[typhoid fever|typhoid]] and [[paratyphoid fever]].<ref>{{cite journal |vauthors=Clarke PD, Geddes AM, McGhie D, Wall JC |title=Mecillinam: a new antibiotic for enteric fever |journal=[[BMJ|Br Med J]] |volume=2 |issue=6026 |pages=14–5 |date=July 1976 |pmid=820402 |pmc=1687648 |doi= 10.1136/bmj.2.6026.14|url=}}</ref><ref>{{cite journal |vauthors=Geddes AM, Clarke PD |title=The treatment of enteric fever with mecillinam |doi=  10.1093/jac/3.suppl_b.101|journal=J Antimicrob Chemother |volume=3 Suppl B |issue= |pages=101–2 |date=July 1977 |pmid=408321|url=}}</ref> Because mecillinam has very low oral [[bioavailability]], an orally active [[prodrug]] was developed: [[pivmecillinam]]. Neither drug is available in the United States.<ref name=POC-IT>{{cite web |url=http://prod.hopkins-abxguide.org/antibiotics/antibacterial/pcn_others/amdinocillin__mecillinam_.html |title=Amdinocillin (Mecillinam) |vauthors=Pham P, Bartlett JG |date=August 28, 2008 |work=Point-of-Care Information Technology ABX Guide |publisher=[[Johns Hopkins University]]}} Retrieved on August 31, 2008. Freely available with registration.</ref>

==Medical uses==
Mecillinam is used in the treatment of infections due to susceptible gram-negative bacteria, especially [[urinary tract infection]]s which are most commonly caused by ''[[Escherichia coli]]''.<ref>{{cite journal|last1=Wagenlehner|first1=FME|last2=Schmiemann|first2=G|last3=Hoyme|first3=U|last4=Fünfstück|first4=R|last5=Hummers-Pradier|first5=E|last6=Kaase|first6=M|last7=Kniehl|first7=E|last8=Selbach|first8=I|last9=Sester|first9=U|last10=Vahlensieck|first10=W|last11=Watermann|first11=D|last12=Naber|first12=KG|title=Nationale S3-Leitlinie "Unkomplizierte Harnwegsinfektionen"|journal=Der Urologe|date=12 February 2011|volume=50|issue=2|pages=153–169|doi=10.1007/s00120-011-2512-z|pmid=21312083|trans_title=National S3 guideline on uncomplicated urinary tract infection: recommendations for treatment and management of uncomplicated community-acquired bacterial urinary tract infections in adult patients|language=German}}</ref> Mecillinam is active against most pathogenic Gram-negative bacteria, except ''[[Pseudomonas aeruginosa]]'' and some species of ''[[Proteus (bacterium)|Proteus]]''.<ref name="POC-IT" /> Several studies have also found it to be as effective as other antibiotics for treating ''[[Staphylococcus saprophyticus]]'' infection, though it is Gram-positive, possibly because mecillinam reaches very high concentrations in urine.<ref name=Nicolle/>

Worldwide [[antibiotic resistance|resistance]] to mecillinam in bacteria causing urinary tract infection has remained very low since its introduction; a 2003 study conducted in 16 European countries and Canada found resistance to range from 1.2% (''[[Escherichia coli]]'') to 5.2% (''[[Proteus mirabilis]]'').<ref>{{cite journal |author=Kahlmeter G |title=An international survey of the antimicrobial susceptibility of pathogens from uncomplicated urinary tract infections: the ECO·SENS Project |journal=J Antimicrob Chemother |volume=51 |issue=1 |pages=69–76 |date=January 2003 |pmid=12493789 |doi= 10.1093/jac/dkg028|url=http://jac.oxfordjournals.org/cgi/pmidlookup?view=long&pmid=12493789}}</ref> Another large study conducted in Europe and [[Brazil]] obtained similar results — 95.9% of ''E. coli'' strains, for instance, were sensitive to mecillinam.<ref>{{cite journal |vauthors=Naber KG, Schito G, Botto H, Palou J, Mazzei T |title=Surveillance Study in Europe and Brazil on Clinical Aspects and Antimicrobial Resistance Epidemiology in Females with Cystitis (ARESC): Implications for Empiric Therapy |journal=Eur Urol |volume= 54|issue= 5|pages= 1164–75|date=May 2008 |pmid=18511178 |doi=10.1016/j.eururo.2008.05.010 |url=}}</ref>

==Adverse effects==
{{see also|Beta-lactam antibiotic#Adverse effects|l1=Beta-lactam antibiotic: Adverse effects}}
The [[adverse drug reaction|adverse effect]] profile of mecillinam is similar to that of other penicillins.<ref name=Neu/> Its most common side effects are [[rash]] and gastrointestinal upset, including [[nausea]] and [[vomiting]].<ref name=Nicolle/>

==History==
With the codename FL 1060, mecillinam was developed by the Danish [[pharmaceutical company]] Leo Pharmaceutical Products (now [[LEO Pharma]]). It was first described in the scientific literature in a 1972 paper.<ref>{{cite journal |vauthors=Lund F, Tybring L |title=6β-amidinopenicillanic acids—a new group of antibiotics |journal=Nature New Biol |volume=236 |issue=66 |pages=135–7 |date=April 1972 |pmid=4402006 |doi=10.1038/236135c0}}</ref><ref>{{cite journal |vauthors=Tybring L, Melchior NH |title=Mecillinam (FL 1060), a 6β-Amidinopenicillanic Acid Derivative: Bactericidal Action and Synergy In Vitro |journal=[[Antimicrobial Agents and Chemotherapy|Antimicrob Agents Chemother]] |volume=8 |issue=3 |pages=271–6 |date=September 1975 |pmid=170856 |pmc=429305 |doi= 10.1128/aac.8.3.271|url=http://aac.asm.org/cgi/pmidlookup?view=long&pmid=170856}}</ref>

==References==
{{Reflist}}
{{Clear}}
{{Beta-lactam antibiotics}}

[[Category:Penicillins]]
[[Category:Enantiopure drugs]]
[[Category:Azepanes]]